Alnylam Pharmaceuticals drug Onpattro, an FDA-approved treatment for nerve pain caused by hereditary transthyretin amyloidosis, now has Phase 3 data showing it can also help the much larger ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July ...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best stocks added in a Growth Stock Portfolio. BMO Capital maintained an ‘Outperform’ rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $339.39, a high estimate of $500.00, and a low estimate of $268.00.

Present Market Standing of Alnylam Pharmaceuticals With a volume of 918,360, the price of ALNY is up 1.19% at $257.76. RSI indicators hint that the underlying stock may be overbought. Next ...

Oct 9 (Reuters) - Alnylam Pharmaceuticals , opens new tab said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug ...

Alnylam Pharmaceuticals has seen its stock rise by 17% this year. The stock now trades at over 33x projected 2020 revenues, despite the fact that the company is likely to post another loss this year.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported strong financial growth in its Q4 2024 results. The company’s total net product revenue for 2024 reached $1.646 billion, a 33% increase from ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: According to 12 analyst offering 12-month price targets in the last 3 months, Alnylam ...